Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. News
  7. Summary
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Genmab A/S : Says Darzalex Sales in Q2 Hit $1.43 Billion

07/21/2021 | 08:23am EDT


© MT Newswires 2021
All news about GENMAB A/S
08:44aGENMAB A/S : Jefferies & Co Downgrades Genmab A/S to Hold From Buy
MT
09/10ABBVIE : Clinical Trial of Investigational Epcoritamab (DuoBody-CD3xCD20) in Pat..
AQ
09/09GENMAB A/S : The Lancet Publishes Positive Results Of Genmab's Epcoritamab Phase..
MT
09/09GENMAB A/S : Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) i..
AQ
09/09Genmab A/S Announces the Lancet Published the Results of FIH Trial
CI
09/07GENMAB A/S : Morgan Stanley Downgrades Genmab to Underweight from Equalweight, K..
MT
09/01CANTARGIA : strengthens the company management team
AQ
08/30MORGAN STANLEY : Genmab to Present at Morgan Stanley 19th Annual Global Healthca..
AQ
08/27PRESS RELEASE : Joint Communiqué: BioNTech Evaluates mRNA Vaccine Manufacturing ..
DJ
08/27GENMAB A/S : to Present at Morgan Stanley 19th Annual Global Healthcare Conferen..
AQ
More news
Analyst Recommendations on GENMAB A/S
More recommendations
Financials
Sales 2021 8 025 M 1 271 M 1 271 M
Net income 2021 2 218 M 351 M 351 M
Net cash 2021 15 357 M 2 431 M 2 431 M
P/E ratio 2021 80,5x
Yield 2021 -
Capitalization 174 B 27 526 M 27 555 M
EV / Sales 2021 19,8x
EV / Sales 2022 14,7x
Nbr of Employees 1 029
Free-Float 94,9%
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 2 662,00 DKK
Average target price 2 754,36 DKK
Spread / Average Target 3,47%
EPS Revisions
Managers and Directors
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Anthony Mancini Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GENMAB A/S9.70%28 072
GILEAD SCIENCES, INC.23.17%89 973
BIONTECH SE335.78%85 800
REGENERON PHARMACEUTICALS34.96%67 787
WUXI APPTEC CO., LTD.28.41%64 886
VERTEX PHARMACEUTICALS-20.09%48 996